Pancreatic Cancer Research

ResearcherNational Institutes of HealthNo recent work listed

Christopher William Schultz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5731-2847; OpenAlex author ID A5015054955. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2019: 3 papers · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper

Papers 12

  1. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancrea… First author DOI 10.1136/bmjopen-2023-073839↗
  2. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00018-22↗
  3. Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model. Co-author DOI 10.1080/15384047.2021.1881026↗
  4. Splenic-vasculature involvement is associated with poor prognosis in resected distal pancreatic cancer. Co-author DOI 10.1093/gastro/goaa084↗
  5. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Co-author DOI 10.1158/1535-7163.mct-20-0652↗
  6. Margin-Positive Pancreatic Ductal Adenocarcinoma during Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival. Co-author DOI 10.1245/s10434-020-09000-9↗
  7. Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression. Co-author DOI 10.1016/j.jamcollsurg.2019.12.033↗
  8. ASO Author Reflections: Margin-Positive Pancreatic Ductal Adenocarcinoma During Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival. Co-author DOI 10.1245/s10434-020-09031-2↗
  9. Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer. Co-author DOI 10.4292/wjgpt.v11.i2.25↗
  10. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗
  11. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. First author DOI 10.1158/1535-7163.mct-19-0208↗
  12. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. First author DOI 10.1158/1541-7786.mcr-19-0589↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Charles J. Yeo · 8 shared papers, 2019–2023 · strength 0.88
  2. Jonathan Robert Brody · 8 shared papers, 2019–2023 · strength 0.86
  3. Avinoam Nevler · 5 shared papers, 2019–2023 · strength 0.56
  4. Harish Lavu · 4 shared papers, 2020–2023 · strength 0.51
  5. Richard Zheng · 4 shared papers, 2020–2021 · strength 0.42
  6. Samantha Z. Brown · 4 shared papers, 2019–2022 · strength 0.40
  7. Wei Jiang · 4 shared papers, 2019–2022 · strength 0.39
  8. Grace A. McCarthy · 4 shared papers, 2019–2022 · strength 0.39
  9. Teena Dhir · 4 shared papers, 2019–2021 · strength 0.37
  10. Aditi Jain · 4 shared papers, 2019–2022 · strength 0.37
  11. Michael Jon Pishvaian · 4 shared papers, 2019–2021 · strength 0.36
  12. David O. Nauheim · 3 shared papers, 2020–2021 · strength 0.34
  13. Theresa Pluth Yeo · 2 shared papers, 2020–2023 · strength 0.27
  14. James A. Posey · 2 shared papers, 2019–2023 · strength 0.25
  15. Talia Golan · 3 shared papers, 2019–2021 · strength 0.24
  16. Adam C. Berger · 2 shared papers, 2020–2021 · strength 0.24
  17. Matthew McCoy · 2 shared papers, 2021–2022 · strength 0.22
  18. Dan A. Dixon · 2 shared papers, 2021–2022 · strength 0.22
  19. Xiuli Liu · 2 shared papers, 2020–2021 · strength 0.19
  20. Xuefeng Zhang · 2 shared papers, 2020–2021 · strength 0.19
  21. Hao Xie · 2 shared papers, 2020–2021 · strength 0.19
  22. Bing Ren · 2 shared papers, 2020–2021 · strength 0.19
  23. Feng Yin · 2 shared papers, 2020–2021 · strength 0.19
  24. Francesca Ponzini · 1 shared paper, 2023 · strength 0.17
  25. Thomas Lee Sutton · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.